Karen Seibert

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Living Beings

Disorders

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Gierse James K; Zhang Yan; Hood William F; Walker Mark C; Trigg Jennifer S; Maziasz Timothy J; Koboldt Carol M; Muhammad Jerry L; Zweifel Ben S; Masferrer Jaime L; Isakson Peter C; Seibert Karen
Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.
Hood William F; Gierse James K; Isakson Peter C; Kiefer James R; Kurumbail Ravi G; Seibert Karen; Monahan Joseph B
Characterization of celecoxib and valdecoxib binding to cyclooxygenase.
Ciceri Paola; Zhang Yan; Shaffer Alex F; Leahy Kathleen M; Woerner Mark B; Smith Walter G; Seibert Karen; Isakson Peter C
Pharmacology of celecoxib in rat brain after kainate administration.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Karen Seibert (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2005: Gierse James K; Zhang Yan; Hood William F; Walker Mark C; Trigg Jennifer S; Maziasz Timothy J; Koboldt Carol M; Muhammad Jerry L; Zweifel Ben S; Masferrer Jaime L; Isakson Peter C; Seibert Karen
Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.
The Journal of pharmacology and experimental therapeutics 2005;312(3):1206-12.
2003: Hood William F; Gierse James K; Isakson Peter C; Kiefer James R; Kurumbail Ravi G; Seibert Karen; Monahan Joseph B
Characterization of celecoxib and valdecoxib binding to cyclooxygenase.
Molecular pharmacology 2003;63(4):870-7.
2002: Ciceri Paola; Zhang Yan; Shaffer Alex F; Leahy Kathleen M; Woerner Mark B; Smith Walter G; Seibert Karen; Isakson Peter C
Pharmacology of celecoxib in rat brain after kainate administration.
The Journal of pharmacology and experimental therapeutics 2002;302(3):846-52.
2002: Hardy Medora M; Seibert Karen; Manning Pamela T; Currie Mark G; Woerner B Mark; Edwards Dorothy; Koki Alane; Tripp Catherine S
Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants.
Arthritis and rheumatism 2002;46(7):1789-803.
2002: Koki A T; Khan N K; Woerner B M; Seibert K; Harmon J L; Dannenberg A J; Soslow R A; Masferrer J L
Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: evidence for potential clinical utility of COX-2 inhibitors in epithelial cancers.
Prostaglandins, leukotrienes, and essential fatty acids 2002;66(1):13-8.
2002: Gierse James; Kurumbail Ravi; Walker Mark; Hood Bill; Monahan Joe; Pawlitz Jennifer; Stegeman Rick; Stevens Anna; Kiefer Jim; Koboldt Carol; Moreland Kirby; Rowlinson Scott; Marnett Larry; Pierce Jennifer; Carter Jeff; Talley John; Isakson Peter; Seibert Karen
Mechanism of inhibition of novel COX-2 inhibitors.
Advances in experimental medicine and biology 2002;507():365-9.
2002: Koki Alane; Khan Nasir K; Woerner B Mark; Dannenberg A J; Olson Lisa; Seibert Karen; Edwards Dorothy; Hardy Madorra; Isakson Peter; Masferrer Jaime L
Cyclooxygenase-2 in human pathological disease.
Advances in experimental medicine and biology 2002;507():177-84.
2002: Gierse James K; Staten Nicholas R; Casperson Gerald F; Koboldt Carol M; Trigg Jennifer S; Reitz Beverly A; Pierce Jennifer L; Seibert Karen
Cloning, expression, and selective inhibition of canine cyclooxygenase-1 and cyclooxygenase-2.
Veterinary therapeutics : research in applied veterinary medicine 2002;3(3):270-80.
2001: Abou-Issa H M; Alshafie G A; Seibert K; Koki A T; Masferrer J L; Harris R E
Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis.
Anticancer research 2001;21(5):3425-32.
2001: Walker M C; Kurumbail R G; Kiefer J R; Moreland K T; Koboldt C M; Isakson P C; Seibert K; Gierse J K
A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors.
The Biochemical journal 2001;357(Pt 3):709-18.
2000: Alshafie G A; Abou-Issa H M; Seibert K; Harris R E
Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model.
Oncology reports 2000;7(6):1377-81.
2000: Grubbs C J; Lubet R A; Koki A T; Leahy K M; Masferrer J L; Steele V E; Kelloff G J; Hill D L; Seibert K
Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats.
Cancer research 2000;60(20):5599-602.
2000: Khanna I K; Yu Y; Huff R M; Weier R M; Xu X; Koszyk F J; Collins P W; Cogburn J N; Isakson P C; Koboldt C M; Masferrer J L; Perkins W E; Seibert K; Veenhuizen A W; Yuan J; Yang D C; Zhang Y Y
Selective cyclooxygenase-2 inhibitors: heteroaryl modified 1,2-diarylimidazoles are potent, orally active antiinflammatory agents.
Journal of medicinal chemistry 2000;43(16):3168-85.
2000: Talley J J; Bertenshaw S R; Brown D L; Carter J S; Graneto M J; Kellogg M S; Koboldt C M; Yuan J; Zhang Y Y; Seibert K
N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration.
Journal of medicinal chemistry 2000;43(9):1661-3.
2000: Harris R E; Alshafie G A; Abou-Issa H; Seibert K
Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor.
Cancer research 2000;60(8):2101-3.
2000: Masferrer J L; Leahy K M; Koki A T; Zweifel B S; Settle S L; Woerner B M; Edwards D A; Flickinger A G; Moore R J; Seibert K
Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.
Cancer research 2000;60(5):1306-11.
2000: Talley J J; Brown D L; Carter J S; Graneto M J; Koboldt C M; Masferrer J L; Perkins W E; Rogers R S; Shaffer A F; Zhang Y Y; Zweifel B S; Seibert K
4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2.
Journal of medicinal chemistry 2000;43(5):775-7.
1999: Seibert K; Lefkowith J; Tripp C; Isakson P; Needleman P
COX-2 inhibitors--is there cause for concern?
Nature medicine 1999;5(6):621-2.
1999: Talley J J; Bertenshaw S R; Brown D L; Carter J S; Graneto M J; Koboldt C M; Masferrer J L; Norman B H; Rogier D J; Zwwifel B S; Seibert K
4,5-Diaryloxazole inhibitors of cyclooxygenase-2 (COX-2).
Medicinal research reviews 1999;19(3):199-208.
1999: Gierse J K; Koboldt C M; Walker M C; Seibert K; Isakson P C
Kinetic basis for selective inhibition of cyclo-oxygenases.
The Biochemical journal 1999;339 ( Pt 3)():607-14.
1999: Carter J S; Kramer S; Talley J J; Penning T; Collins P; Graneto M J; Seibert K; Koboldt C M; Masferrer J; Zweifel B
Synthesis and activity of sulfonamide-substituted 4,5-diaryl thiazoles as selective cyclooxygenase-2 inhibitors.
Bioorganic & medicinal chemistry letters 1999;9(8):1171-4.
1999: Carter J S; Rogier D J; Graneto M J; Seibert K; Koboldt C M; Zhang Y; Talley J J
Design and synthesis of sulfonyl-substituted 4,5-diarylthiazoles as selective cyclooxygenase-2 inhibitors.
Bioorganic & medicinal chemistry letters 1999;9(8):1167-70.
1999: Masferrer J L; Koki A; Seibert K
COX-2 inhibitors. A new class of antiangiogenic agents.
Annals of the New York Academy of Sciences 1999;889():84-6.
1998: Smith C J; Zhang Y; Koboldt C M; Muhammad J; Zweifel B S; Shaffer A; Talley J J; Masferrer J L; Seibert K; Isakson P C
Pharmacological analysis of cyclooxygenase-1 in inflammation.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(22):13313-8.
1997: Zhang Y; Shaffer A; Portanova J; Seibert K; Isakson P C
Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production.
The Journal of pharmacology and experimental therapeutics 1997;283(3):1069-75.
1997: Khanna I K; Weier R M; Yu Y; Xu X D; Koszyk F J; Collins P W; Koboldt C M; Veenhuizen A W; Perkins W E; Casler J J; Masferrer J L; Zhang Y Y; Gregory S A; Seibert K; Isakson P C
1,2-Diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active antiinflammatory agents.
Journal of medicinal chemistry 1997;40(11):1634-47.
1997: Khanna I K; Weier R M; Yu Y; Collins P W; Miyashiro J M; Koboldt C M; Veenhuizen A W; Currie J L; Seibert K; Isakson P C
1,2-Diarylpyrroles as potent and selective inhibitors of cyclooxygenase-2.
Journal of medicinal chemistry 1997;40(11):1619-33.
1997: Penning T D; Talley J J; Bertenshaw S R; Carter J S; Collins P W; Docter S; Graneto M J; Lee L F; Malecha J W; Miyashiro J M; Rogers R S; Rogier D J; Yu S S; AndersonGD; Burton E G; Cogburn J N; Gregory S A; Koboldt C M; Perkins W E; Seibert K; Veenhuizen A W; Zhang Y Y; Isakson P C
Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).
Journal of medicinal chemistry 1997;40(9):1347-65.
1997: Seibert K; Zhang Y; Leahy K; Hauser S; Masferrer J; Isakson P
Distribution of COX-1 and COX-2 in normal and inflamed tissues.
Advances in experimental medicine and biology 1997;400A():167-70.
1996: Portanova J P; Zhang Y; Anderson G D; Hauser S D; Masferrer J L; Seibert K; Gregory S A; Isakson P C
Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo.
The Journal of experimental medicine 1996;184(3):883-91.
1996: Masferrer J L; Isakson P C; Seibert K
Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract.
Gastroenterology clinics of North America 1996;25(2):363-72.
1996: Gierse J K; McDonald J J; Hauser S D; Rangwala S H; Koboldt C M; Seibert K
A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors.
The Journal of biological chemistry 1996;271(26):15810-4.
1996: Li J J; Norton M B; Reinhard E J; Anderson G D; Gregory S A; Isakson P C; Koboldt C M; Masferrer J L; Perkins W E; Seibert K; Zhang Y; Zweifel B S; Reitz D B
Novel terphenyls as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents.
Journal of medicinal chemistry 1996;39(9):1846-56.
1996: Seibert K; Masferrer J L; Needleman P; Salvemini D
Pharmacological manipulation of cyclo-oxygenase-2 in the inflamed hydronephrotic kidney.
British journal of pharmacology 1996;117(6):1016-20.
1996: Huang H C; Li J J; Garland D J; Chamberlain T S; Reinhard E J; Manning R E; Seibert K; Koboldt C M; Gregory S A; Anderson G D; Veenhuizen A W; Zhang Y; Perkins W E; Burton E G; Cogburn J N; Isakson P C; Reitz D B
Diarylspiro[2.4]heptenes as orally active, highly selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationships.
Journal of medicinal chemistry 1996;39(1):253-66.
1995: Huff R; Collins P; Kramer S; Seibert K; Koboldt C; Gregory S; Isakson P
A structural feature of N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulfonamide (NS-398) that governs its selectivity and affinity for cyclooxygenase 2 (COX2).
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 1995;44 Suppl 2():S145-6.
1995: Salvemini D; Manning P T; Zweifel B S; Seibert K; Connor J; Currie M G; Needleman P; Masferrer J L
Dual inhibition of nitric oxide and prostaglandin production contributes to the antiinflammatory properties of nitric oxide synthase inhibitors.
The Journal of clinical investigation 1995;96(1):301-8.
1995: Salvemini D; Settle S L; Masferrer J L; Seibert K; Currie M G; Needleman P
Regulation of prostaglandin production by nitric oxide; an in vivo analysis.
British journal of pharmacology 1995;114(6):1171-8.
1995: Gierse J K; Hauser S D; Creely D P; Koboldt C; Rangwala S H; Isakson P C; Seibert K
Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase.
The Biochemical journal 1995;305 ( Pt 2)():479-84.
1995: Seibert K; Masferrer J; Zhang Y; Leahy K; Hauser S; Gierse J; Koboldt C; Anderson G; Bremer M; Gregory S
Expression and selective inhibition of constitutive and inducible forms of cyclooxygenase.
Advances in prostaglandin, thromboxane, and leukotriene research 1995;23():125-7.
1995: Isakson P; Seibert K; Masferrer J; Salvemini D; Lee L; Needleman P
Discovery of a better aspirin.
Advances in prostaglandin, thromboxane, and leukotriene research 1995;23():49-54.
1995: Seibert K; Masferrer J; Zhang Y; Gregory S; Olson G; Hauser S; Leahy K; Perkins W; Isakson P
Mediation of inflammation by cyclooxygenase-2.
Agents and actions. Supplements 1995;46():41-50.
1995: Salvemini D; Seibert K; Masferrer J L; Settle S L; Misko T P; Currie M G; Needleman P
Nitric oxide and the cyclooxygenase pathway.
Advances in prostaglandin, thromboxane, and leukotriene research 1995;23():491-3.
1994: Seibert K; Zhang Y; Leahy K; Hauser S; Masferrer J; Perkins W; Lee L; Isakson P
Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(25):12013-7.
1994: Reitz D B; Li J J; Norton M B; Reinhard E J; Collins J T; Anderson G D; Gregory S A; Koboldt C M; Perkins W E; Seibert K
Selective cyclooxygenase inhibitors: novel 1,2-diarylcyclopentenes are potent and orally active COX-2 inhibitors.
Journal of medicinal chemistry 1994;37(23):3878-81.
1994: Isakson P; Hauser S; Zhang Y; Leahy K; Masferrer J; Seibert K
Cytokine regulation of eicosanoid generation.
Annals of the New York Academy of Sciences 1994;744():181-3.
1994: Masferrer J L; Reddy S T; Zweifel B S; Seibert K; Needleman P; Gilbert R S; Herschman H R
In vivo glucocorticoids regulate cyclooxygenase-2 but not cyclooxygenase-1 in peritoneal macrophages.
The Journal of pharmacology and experimental therapeutics 1994;270(3):1340-4.
1994: Salvemini D; Seibert K; Masferrer J L; Misko T P; Currie M G; Needleman P
Endogenous nitric oxide enhances prostaglandin production in a model of renal inflammation.
The Journal of clinical investigation 1994;93(5):1940-7.
1994: Masferrer J L; Zweifel B S; Manning P T; Hauser S D; Leahy K M; Smith W G; Isakson P C; Seibert K
Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(8):3228-32.
1994: Masferrer J L; Seibert K
Regulation of prostaglandin synthesis by glucocorticoids.
Receptor 1994;4(1):25-30.
1994: Seibert K; Masferrer J L
Role of inducible cyclooxygenase (COX-2) in inflammation.
Receptor 1994;4(1):17-23.
1993: Salvemini D; Misko T P; Masferrer J L; Seibert K; Currie M G; Needleman P
Nitric oxide activates cyclooxygenase enzymes.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(15):7240-4.
1992: Masferrer J L; Seibert K; Zweifel B; Needleman P
Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(9):3917-21.
1991: Seibert K; Masferrer J L; FU J Y; Honda A; Raz A; Needleman P
The biochemical and pharmacological manipulation of cellular cyclooxygenase (COX) activity.
Advances in prostaglandin, thromboxane, and leukotriene research 1991;21A():45-51.
1990: Masferrer J L; Zweifel B S; Seibert K; Needleman P
Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice.
The Journal of clinical investigation 1990;86(4):1375-9.
1990: Fu J Y; Masferrer J L; Seibert K; Raz A; Needleman P
The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes.
The Journal of biological chemistry 1990;265(28):16737-40.
1990: Raz A; Wyche A; Fu J; Seibert K; Needleman P
Regulation of prostanoids synthesis in human fibroblasts and human blood monocytes by interleukin-1, endotoxin, and glucocorticoids.
Advances in prostaglandin, thromboxane, and leukotriene research 1990;20():22-7.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Karen Seibert

Research Profile (preview)

Chemicals & Drugs

Living Beings

Disorders

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Karen Seibert (preview)

All Publications